These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16394842)

  • 1. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Vezina HE; Henry K; Ravindran GD; Kurpad AV; Raj TD; Fox K; Weller D; Brundage RC; Cavert W; Balfour HH
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):131-6. PubMed ID: 16394842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    Byakika-Tusiime J; Chinn LW; Oyugi JH; Obua C; Bangsberg DR; Kroetz DL
    PLoS One; 2008; 3(12):e3981. PubMed ID: 19096711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
    Hosseinipour MC; Corbett AH; Kanyama C; Mshali I; Phakati S; Rezk NL; van der Horst C; Kashuba AD
    AIDS; 2007 Jan; 21(1):59-64. PubMed ID: 17148968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized pahse I bioequivalence clinincal trial of a paediatric fixed-dose combination antiretroviral reconstitutable suspension in healthy adult volunteers.
    Esseku F; Joshi A; Oyegbile Y; Edowhorhu G; Gbadero D; Adeyeye M
    Antivir Ther; 2013; 18(2):205-12. PubMed ID: 23653910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption.
    Moore KH; Shaw S; Laurent AL; Lloyd P; Duncan B; Morris DM; O'Mara MJ; Pakes GE
    J Clin Pharmacol; 1999 Jun; 39(6):593-605. PubMed ID: 10354963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.
    Dos Reis Serra CH; Mori Koono EE; Kano EK; Schramm SG; Armando YP; Porta V
    Clin Ther; 2008 May; 30(5):902-8. PubMed ID: 18555936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
    Marier JF; Dimarco M; Guilbaud R; Dodard C; Morelli G; Tippabhotla SK; Singla AK; Thudi NR; Monif T
    J Clin Pharmacol; 2007 Nov; 47(11):1381-9. PubMed ID: 17962426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized two-way crossover bioequivalence study in healthy adult volunteers of paediatric zidovudine/lamivudine/nevirapine fast-disintegrating fixed-dose combination tablet.
    Joshi A; Gbadero D; Esseku F; Adesanya OJ; Adeyeye MC
    J Pharm Pharmacol; 2017 Apr; 69(4):463-470. PubMed ID: 27859251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
    Mukherjee A; Singla M; Velpandian T; Sirohiwal A; Vajpayee M; Singh R; Kabra SK; Lodha R
    Indian Pediatr; 2014 Mar; 51(3):191-7. PubMed ID: 24736906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Corbett AH; Hosseinipour MC; Nyirenda J; Kanyama C; Rezk NL; Mkupani P; Sichali D; Tien H; Kashuba AD; Mwansambo C; Weigel R; Kazembe P
    Antivir Ther; 2010; 15(1):83-90. PubMed ID: 20167994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative bioavailability study of zidovudine administered as two different tablet formulations in healthy adult subjects.
    Marier JF; Manthos H; Kebir S; Ferron S; DiMarco M; Morelli G; Tippabhotla SK; Vijan T; Singla AK; Garg M; Monif T
    Int J Clin Pharmacol Ther; 2006 May; 44(5):240-6. PubMed ID: 16724579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
    Burger D; Ewings F; Kabamba D; L'homme R; Mulenga V; Kankasa C; Thomason M; Gibb DM; Chintu C; Walker AS
    Ther Drug Monit; 2010 Jun; 32(3):369-72. PubMed ID: 20386361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing in vitro/in vivo assessment of fixed dose combination products of first line antiretrovirals.
    Joshi A; Esseku F; Silva L; Igwilo C; Oqua D; Kunle B; Obodozie O; Inyang U; Adeyeye MC
    J Pharm Sci; 2010 Jun; 99(6):2655-63. PubMed ID: 20054854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
    Byakika-Kibwika P; Lamorde M; Kalemeera F; D'Avolio A; Mauro S; Di Perri G; Ryan M; Mayanja-Kizza H; Khoo S; Back D; Boffito M; Merry C
    J Antimicrob Chemother; 2008 Nov; 62(5):1113-7. PubMed ID: 18641036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycophenolate mofetil 500-mg tablet under fasting conditions: single-dose, randomized-sequence, open-label, four-way replicate crossover, bioequivalence study in healthy subjects.
    Almeida S; Filipe A; Neves R; Spínola AC; Tanguay M; Ortuño J; Farré A; Torns A
    Clin Ther; 2010 Mar; 32(3):556-74. PubMed ID: 20399993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.